Effectiveness of phosphocitrate and N-sulpho-2-amino tricarballylate, a new analogue of phosphocitrate, in blocking hydroxyapatite induced crystal growth and calcium accumulation by matrix vesicles.
Phosphocitrate and its analogue N-sulpho-2-amino tricarballylate were compared with ethane-1-hydroxy-1,1-diphosphonate for inhibition of calcium phosphate crystallization in hydroxyapatite induced crystal growth and 45Ca uptake by matrix vesicles. Phosphocitrate (1 microM) was the most potent inhibitor followed by ethane-1-hydroxy-1,1-diphosphonate and N-sulpho-2-amino tricarballylate, the latter requiring a high concentration (100 microM) to be equally effective as an inhibitor.
D000818:Animals; D002118:Calcium / Q000378:metabolism*; D002356:Cartilage / Q000187:drug effects / Q000378:metabolism*; D002645:Chickens; D002951:Citrates / Q000494:pharmacology*; D003460:Crystallization; D017886:Durapatite; D012968:Etidronic Acid / Q000494:pharmacology; D006882:Hydroxyapatites / Q000494:pharmacology*; D014233:Tricarboxylic Acids / Q000494:pharmacology*
D002951:Citrates; D006882:Hydroxyapatites; D014233:Tricarboxylic Acids; C014148:phosphocitrate; C039013:N-sulfo-2-aminotricarballylate; D017886:Durapatite; D012968:Etidronic Acid; D002118:Calcium